QRS duration before and after disopyramide infusion
| Before disopyramide | After disopyramide | Statistics (p value) | |||||
|---|---|---|---|---|---|---|---|
| Lead | Deteriorated (n=8) (ms) | Unchanged (n=5) (ms) | Deteriorated (n=8) (ms) | Unchanged (n=5) (ms) | Group factor | Drug factor | Interaction |
| Values are mean (SD). | |||||||
| *Significant difference before and after disopyramide. | |||||||
| I | 96 (25) | 86 (10) | 118 (31) | 96 (8) | 0.23 | <0.01* | 0.12 |
| II | 111 (25) | 105 (17) | 124 (29) | 112 (11) | 0.53 | 0.03* | 0.53 |
| III | 103 (16) | 110 (14) | 115 (18) | 121 (8) | 0.41 | <0.01* | 0.94 |
| aVR | 104 (27) | 101 (16) | 119 (26) | 113 (15) | 0.74 | <0.01* | 0.54 |
| aVL | 107 (27) | 94 (17) | 110 (27) | 105 (16) | 0.47 | <0.01* | 0.06 |
| aVF | 111 (27) | 111 (17) | 122 (27) | 116 (9) | 0.84 | <0.01* | 0.20 |
| V1 | 114 (16) | 104 (12) | 128 (14) | 114 (12) | 0.14 | <0.01* | 0.56 |
| V2 | 108 (13) | 100 (8) | 131 (15) | 110 (7) | 0.06 | <0.01* | <0.01* |
| V3 | 117 (16) | 106 (9) | 132 (13) | 114 (10) | 0.06 | <0.01* | 0.07 |
| V4 | 117 (22) | 102 (10) | 131 (20) | 113 (7) | 0.14 | <0.01* | 0.53 |
| V5 | 109 (21) | 103 (15) | 123 (18) | 111 (12) | 0.39 | <0.01* | 0.21 |
| V6 | 104 (21) | 102 (15) | 120 (25) | 112 (14) | 0.68 | <0.01* | 0.31 |